B cells set trends: Lessons from multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Research Focuses and Trends in Multiple Sclerosis: A Scientometric Analysis
The purpose of this scientometric study is to analyze the multiple sclerosis research in Science Citation Index-Expanded from 1992 to 2019 in order to determine the top features, trends, and topics. Articles related to multiple sclerosis in the section of title, abstract, keywords, and KeyWords Plus were retrieved from the Science Citation Index-Expanded and analyzed based on various indicators...
متن کاملTargeting “bad” B cells in multiple sclerosis
Laquinimod is an orally available quinoline 3carboxamide derivative drug studied in phase II and III clinical trials for relapsing-remitting multiple sclerosis (RRMS), systemic lupus erythematosus, and Crohn disease. Laquinimod has shown promise in RRMS clinical trials, and identifying the mechanism underlying its disease-modifying effects could help target it to the patient population where it...
متن کاملB Cells and Autoantibodies in Multiple Sclerosis
While over the past decades T cells have been considered key players in the pathogenesis of multiple sclerosis (MS), it has only recently become evident that B cells have a major contributing role. Our understanding of the role of B cells has evolved substantially following the clinical success of B cell-targeting therapies and increasing experimental evidence for significant B cell involvement...
متن کاملP 140: Stem Cells in Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS). Inflammation caused by immune cells destroy the myelin and then axon. CNS failure to complete repair results in permanent disabilities. Some types of stem cells have special potentials to repair these injuries and even cure MS. Neural crest stem cells with a mutual origin with CNS and the ability of differen...
متن کاملTrends in managing multiple sclerosis.
Almost 23% of MCOs noted that they plan to implement these first two strategies in the next 12 to 18 months, whereas 35% expect to implement the differential prior authorization. In the survey, 32% of MCOs had already put in place tiered coverage with significant cost-sharing differentials (above $30) between preferred and non-preferred specialty therapies. As many as 75% of respondents did not...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Experimental Neuroimmunology
سال: 2012
ISSN: 1759-1961
DOI: 10.1111/j.1759-1961.2012.00029.x